Autoimmune lymphoproliferative syndrome laboratory findings: Difference between revisions
| Line 9: | Line 9: | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
In [[peripheral blood]]- | In [[peripheral blood]]-<ref name="OliveiraBleesing2010">{{cite journal|last1=Oliveira|first1=Joao B.|last2=Bleesing|first2=Jack J.|last3=Dianzani|first3=Umberto|last4=Fleisher|first4=Thomas A.|last5=Jaffe|first5=Elaine S.|last6=Lenardo|first6=Michael J.|last7=Rieux-Laucat|first7=Frederic|last8=Siegel|first8=Richard M.|last9=Su|first9=Helen C.|last10=Teachey|first10=David T.|last11=Rao|first11=V. Koneti|title=Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop|journal=Blood|volume=116|issue=14|year=2010|pages=e35–e40|issn=0006-4971|doi=10.1182/blood-2010-04-280347}}</ref> | ||
* Increased [[T cell]] [[receptor]] (TCR) αβ+/CD4-/CD8- [[T cells]] | * Increased [[T cell]] [[receptor]] (TCR) αβ+/CD4-/CD8- [[T cells]] | ||
Revision as of 02:36, 11 August 2021
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome laboratory findings On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome laboratory findings |
|
FDA on Autoimmune lymphoproliferative syndrome laboratory findings |
|
CDC on Autoimmune lymphoproliferative syndrome laboratory findings |
|
Autoimmune lymphoproliferative syndrome laboratory findings in the news |
|
Blogs on Autoimmune lymphoproliferative syndrome laboratory findings |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
|
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome laboratory findings |
Editor-In-Chief: Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] David Teachey, MD [2] Associate Editor(s)-in-Chief: Sharmi Biswas, M.B.B.S
Overview
An elevated concentration of serum double negative α/β T cells comprising more than 1.5% of the total lymphocytes or at least 2.5% of total T cells along with chronic lymphadenopathy or splenomegaly for more than 6 months are the two required testing for clinical diagnosis of Autoimmune lymphoproliferative syndrome which leads to ancillary testing. Confirmatory testing for ALPS is the testing for the ALPS-related mutations or functional testing of patient T cells are requires according to the 2010 guidelines.
Laboratory Findings
- Co-expression of CD45RA,CD57,CD27,CD28, perforin, and HLA-DR in the DNT cells but lacking CD45R0 and CD56
- Cytopenia
- Positive Coombs' test
- Increased soluble FAS ligand (FasL)
- High vitamin B12
- Hypergammaglobulinemia ( increased IgG, IgA,or IgM)
References
- ↑ Oliveira, Joao B.; Bleesing, Jack J.; Dianzani, Umberto; Fleisher, Thomas A.; Jaffe, Elaine S.; Lenardo, Michael J.; Rieux-Laucat, Frederic; Siegel, Richard M.; Su, Helen C.; Teachey, David T.; Rao, V. Koneti (2010). "Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop". Blood. 116 (14): e35–e40. doi:10.1182/blood-2010-04-280347. ISSN 0006-4971.